ConMed Corporation successfully fought off claims that the medical technology company breached its obligation to pursue the development of a medical device following safety concerns.
The dispute in the Delaware Chancery court centered on post-merger payments following ConMed’s 2014 acquisition of EndoDynamix, Inc., a surgical device manufacturer that was developing a medical instrument at the time of the sale.
In a post-trial opinion on Thursday, the court said evidence “overwhelmingly supports” ConMed’s position that it was “commercially reasonable” to drop the product. The New York company’s decision to stop working on the device because it could potentially injure patients was ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
